Shen ZX - Search Results

1

[Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma].

Shen Y, Yao Y, Li JM, Chen QS, You JH, Zhao HJ, Chen S, Shen ZX. Shen Y, et al. Among authors: shen zx. Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):252-7. Zhonghua Xue Ye Xue Za Zhi. 2008. PMID: 18843980 Chinese.

2

Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma.

Liu YY, Leboeuf C, Shi JY, Li JM, Wang L, Shen Y, Garcia JF, Shen ZX, Chen Z, Janin A, Chen SJ, Zhao WL. Liu YY, et al. Among authors: shen y, shen zx. Blood. 2007 Jul 1;110(1):339-44. doi: 10.1182/blood-2006-09-049189. Epub 2007 Mar 22. Blood. 2007. PMID: 17379744 Free article.

3

[Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].

Zhou L, Wang AH, Wang L, You JH, Li JM, Shen ZX. Zhou L, et al. Among authors: shen zx. Zhonghua Xue Ye Xue Za Zhi. 2008 Jan;29(1):13-7. Zhonghua Xue Ye Xue Za Zhi. 2008. PMID: 18512309 Chinese.

4

The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment.

Xia ZG, Xu ZZ, Zhao WL, Zhao SQ, Ding F, Chen Y, Chen QS, Zheng Y, Zhu Q, Hu JP, Shen ZX, Li JM. Xia ZG, et al. Among authors: shen zx. Ann Hematol. 2010 Feb;89(2):171-7. doi: 10.1007/s00277-009-0799-2. Epub 2009 Aug 11. Ann Hematol. 2010. PMID: 19669764

5

[Nilotinib treatment for imatinib resistant or intolerant chronic myelogenous leukemia.].

Wang AH, Zhou L, You JH, Wang L, Li JM, Hu J, Shen ZX. Wang AH, et al. Among authors: shen zx. Zhonghua Xue Ye Xue Za Zhi. 2010 Jan;31(1):11-5. Zhonghua Xue Ye Xue Za Zhi. 2010. PMID: 20302768 Chinese.

6

[Treatment outcome analysis of CTOP or CHOP regimen in newly diagnosed aggressive non-Hodgkin's lymphoma patients-results of a prospective, open, randomized, multicenter clinical trial].

Wang YY, Zhang JL, Wang C, Wang X, Wu DP, Liang H, Zhu J, Li JM, Shen ZX. Wang YY, et al. Among authors: shen zx. Zhonghua Xue Ye Xue Za Zhi. 2010 Oct;31(10):649-53. Zhonghua Xue Ye Xue Za Zhi. 2010. PMID: 21223712 Clinical Trial. Chinese.

7

[Analysis of outocome of pirarubicin-based combination chemotherapy regimen in the treatment of newly diagnosed acute myeloid leukemia-a prospective, open, randomized and multicenter clinical trial].

Wang YY, Sheng XM, Zhang RY, Guo XN, Sun H, Wang X, Zhang JL, Li JM, Shen ZX. Wang YY, et al. Among authors: shen zx. Zhonghua Xue Ye Xue Za Zhi. 2010 Nov;31(11):748-51. Zhonghua Xue Ye Xue Za Zhi. 2010. PMID: 21223729 Chinese.

8

[Clinical features and prognostic analysis of mantle cell lymphoma].

Bao WY, Wang Y, Hu XM, Li JM, Shen ZX, Zhao WL. Bao WY, et al. Among authors: shen zx. Zhonghua Xue Ye Xue Za Zhi. 2012 Oct;33(10):814-8. Zhonghua Xue Ye Xue Za Zhi. 2012. PMID: 23384900 Chinese.

9

[Prognostic analysis of non-cytogenetic factors in elderly adults with acute myeloid leukemia].

Zhao BB, Zhu Z, Xu PP, Li JM, Shen ZX, Zhao WL, Wang L. Zhao BB, et al. Among authors: shen zx. Zhonghua Xue Ye Xue Za Zhi. 2013 Jan;34(1):3-7. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23597455 Chinese.

10

[Prognostic significance of EBMT score system for hematological malignancies with allogeneic hematopoietic stem cell transplantation].

Wang L, Tang W, Fan X, Zhao WL, Chen YB, Shen ZX, Li JM, Hu J. Wang L, et al. Among authors: shen zx. Zhonghua Xue Ye Xue Za Zhi. 2013 Aug;34(8):655-8. doi: 10.3760/cma.j.issn.0253-2727.2013.08.003. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23978014 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

529 results

Search Page

Filters